Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | KCNN2 | Q9H2S1 | 4/20 | 0.67 |
| ▸ | KCNN3 | Q9UGI6 | 4/20 | 0.67 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.65 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29924522 | 1.00 | LMNA (0.81) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL29837028 | 1.00 | LMNA (0.81) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL29748937 | 1.00 | LMNA (0.81) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Hydrochloric Acid SCHEMBL14691397 | 0.99 | LMNA (0.79) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL30816021 | 0.89 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL6130845 | 0.89 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL29822950 | 0.89 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL466528 | 0.89 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| Laudanosine SCHEMBL466529 | 0.89 | LMNA (1.00) | LMNAKDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL8199189 | 0.88 | DRD2 (0.71) | LMNAKDM4EALDH1A1HSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158795-B2 | Process for the purification of neuromuscular blocking agents | FARMABIOS S.P.A. (IT) | 2012-04-17 | — | — | US | claimed |
| US-20100016596-A1 | PROCESS FOR THE PURIFICATION OF NEUROMUSCULAR BLOCKING AGENTS | FARMABIOS S.P.A. (IT) | 2010-01-21 | — | — | US | claimed |
| US-8158795-B2 | Process for the purification of neuromuscular blocking agents | FARMABIOS S.P.A. (IT) | 2012-04-17 | — | — | US | disclosed |
| US-20100016596-A1 | PROCESS FOR THE PURIFICATION OF NEUROMUSCULAR BLOCKING AGENTS | FARMABIOS S.P.A. (IT) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016596-A1 | PROCESS FOR THE PURIFICATION OF NEUROMUSCULAR BLOCKING AGENTS | GLRB, GRIN2C, CHRNA5 | LMNA 2057/4885KDM4E 1550/4885ALDH1A1 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.